Kintor Pharmaceutical's Alopecia Drug Meets Main Goal of Mid-stage Study in China; Shares Rise 3%

MT Newswires Live
07/24

Kintor Pharmaceutical (HKG:9939) said a mid-stage study of its alopecia drug had met its primary goal, according to a Hong Kong bourse filing Thursday.

Shares of the pharmaceutical jumped over 3% in recent morning trade.

Results from the study demonstrated that subjects who applied the company's KX-826 1% tincture experienced significantly more hair growth when compared to the placebo group after 24 weeks of treatment.

The medicine was also found to have an "excellent" favorable safety profile, Kintor said.

The trial enrolled 90 male adult subjects in China with androgenetic alopecia, a condition that causes hair loss.

Based on the results, an independent monitoring committee recommended the company continue with an ongoing phase 3 study of the drug.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10